Literature DB >> 21222588

Improving siRNA bio-distribution and minimizing side effects.

Bruna Scaggiante1, Barbara Dapas, Rossella Farra, Mario Grassi, Gabriele Pozzato, Carlo Giansante, Nicola Fiotti, Gabriele Grassi.   

Abstract

The RNA interference (RNAi) is a biological process by which a double stranded RNA (dsRNA also called small interfering RNA - siRNA) triggers the sequence-dependent degradation of a target RNA within the cellular environment. Thus siRNAs can be used to combat the expression of deleterious gene(s) causing disease or to destroy invading pathogen RNAs. Despite their enormous therapeutic potential, the use of siRNA as drugs presents two major problems: the difficulties to identify optimal delivery systems and the possible induction of different unwanted side effects. In this review, after presenting an overview about the mechanisms ruling the process of RNAi, we focus the attention on the description of the strategies developed to optimise systemic siRNA delivery; in this sense, considerations about the attempts to improve siRNA stability in the biological environment, the development of synthetic vectors for siRNA delivery, the siRNA bio-distribution and pharmacokinetics together with the selection of siRNA targeted delivery systems, are discussed. Since in the optimisation of the siRNA delivery systems the minimization of siRNA side effects should not be neglected, in the last part of the review we consider the problems related to the possible induction of siRNA mediated side effects focusing on the so called microRNA like off-targeting.

Mesh:

Substances:

Year:  2011        PMID: 21222588     DOI: 10.2174/138920011794520017

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  20 in total

Review 1.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 2.  Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.

Authors:  Rossella Farra; Mario Grassi; Gabriele Grassi; Barbara Dapas
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

Review 3.  Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.

Authors:  Yu-Cheng Zhang; Zhuo Xu; Tian-Fu Zhang; Ya-Li Wang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  Sonoporation using microbubbles promotes lipofectamine-mediated siRNA transduction to rat retina.

Authors:  Xiaozhi Zheng; Ping Ji; Jianqun Hu
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

5.  Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression.

Authors:  Linda B Jensen; Joscha Griger; Broes Naeye; Amir K Varkouhi; Koen Raemdonck; Raymond Schiffelers; Twan Lammers; Gert Storm; Stefaan C de Smedt; Brian S Sproat; Hanne M Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2011-10-05       Impact factor: 4.200

Review 6.  Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.

Authors:  Bruna Scaggiante; Maryam Kazemi; Gabriele Pozzato; Barbara Dapas; Rosella Farra; Mario Grassi; Fabrizio Zanconati; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

7.  Can TIE-2 expressing monocytes represent a novel marker for hepatocellular carcinoma?

Authors:  Barbara Dapas; Mario Grassi; Gabriele Grassi
Journal:  Hepatobiliary Surg Nutr       Date:  2014-08       Impact factor: 7.293

Review 8.  MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.

Authors:  Ulrich H Weidle; Daniela Schmid; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2020 Jan-Feb       Impact factor: 4.069

Review 9.  SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.

Authors:  Ramalingam Karthik Raja; Phuong Nguyen-Tri; Govindasamy Balasubramani; Arun Alagarsamy; Selcuk Hazir; Safa Ladhari; Alireza Saidi; Arivalagan Pugazhendhi; Arulandhu Anthoni Samy
Journal:  Appl Nanosci       Date:  2021-06-10       Impact factor: 3.869

10.  Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6.

Authors:  Gareth D Healey; Jennifer A Lockridge; Shawn Zinnen; Julian M Hopkin; Ivan Richards; William Walker
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.